Kezar Raises $50M to Support Development of KZR-616 for Autoimmune Diseases

Kezar Raises $50M to Support Development of KZR-616 for Autoimmune Diseases
Kezar Life Sciences raised $50 million in a financing round to support further clinical development of its lead drug candidate KZR-616 for the treatment of several autoimmune and inflammatory diseases, including Crohn’s disease. The announcement comes on the heels of the successful completion of Kezar’s Phase 1a trial in Australia (ACTRN12616001040459) in healthy volunteers to evaluate

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *